Heading into 2024, expectations for biotech venture capital (VC) and private equity (PE) investments were low following two lackluster years, but as we wrap up Q1, those expectations have been turned on their head after a...more
The combined health and economic crisis caused by the outbreak of coronavirus (COVID-19) and subsequent isolation efforts across the world have left many emerging-growth companies with numerous questions about how to get...more